Natural Alternatives to Ozempic: Can Olive Oil Polyphenols Support GLP-1 and Weight Loss?

The world is looking for natural GLP-1 alternatives. Here is what the science actually says about olive oil polyphenols, gut hormones, and metabolic health -- and where the evidence stands right now.

Quick Summary

• GLP-1 drugs like Ozempic work by mimicking a gut hormone that reduces appetite, slows digestion, and lowers blood sugar. They produce significant weight loss but come with gastrointestinal side effects, muscle and bone density loss, emerging concerns around dampened desire and libido, high cost, and weight regain when discontinued.

• Extra virgin olive oil stimulates your body's own GLP-1 production. Multiple clinical studies show EVOO increases postprandial GLP-1 and PYY (satiety hormones) while reducing ghrelin (the hunger hormone), through mechanisms that partially overlap with what GLP-1 drugs do pharmacologically.

• The active compounds are olive oil polyphenols -- specifically hydroxytyrosol, oleocanthal, oleuropein, and elenolic acid. These are unique to olive oil and distinct from polyphenols found in other foods like berries, tea, or wine. They interact with metabolic signalling pathways that influence inflammation, insulin sensitivity, and gut hormone secretion.

• Olive oil is not a drug replacement. The magnitude of effect is different. But the evidence supports high-polyphenol EVOO as a meaningful, evidence-based nutritional tool for metabolic health -- one that works with your biology rather than overriding it.

• Polyphenol content varies enormously. Standard supermarket EVOO contains 50-100 mg/kg of polyphenols. Nutraceutical-grade oils like Oleaphen exceed 2,000 mg/kg. The EU health claim requires a minimum of 250 mg/kg.

The GLP-1 drug revolution has changed how the world thinks about weight loss. Medications like Ozempic and Wegovy have moved from diabetes clinics into mainstream culture, generating billions in revenue and spawning an entire industry of before-and-after transformations. The mechanism is elegant: mimic a gut hormone that tells your brain you are full, and appetite drops dramatically.

But what if that same gut hormone -- GLP-1 -- could be nudged naturally? Not by a weekly injection, but by compounds that have been part of the human diet for millennia? Recent research into olive oil polyphenols, particularly from extra virgin olive oil, is beginning to reveal a surprisingly rich biochemical conversation between what we eat and the hormones that regulate hunger, metabolism, and body weight.

This is not a story about replacing pharmaceuticals with food. It is a story about understanding the metabolic logic your body already uses -- and whether the right dietary inputs can support it.

The GLP-1 Revolution, its Limits and side effects

Glucagon-like peptide-1 (GLP-1) is a hormone produced by L-cells in the gut lining every time you eat. It serves multiple purposes: it stimulates insulin secretion in response to rising blood sugar, slows gastric emptying so food stays in your stomach longer, and sends satiety signals to the brain that reduce appetite. GLP-1 receptor agonists like semaglutide (marketed as Ozempic for diabetes and Wegovy for weight management) use a synthetic version of this hormone to activate GLP-1 receptors more powerfully and for longer than the natural hormone does.

The results have been striking. Clinical trials show weight loss averaging 15-17% of body weight over a year. Users frequently describe the disappearance of "food noise" -- the constant background preoccupation with eating that many people experience. Research presented at the 2025 European Association for the Study of Diabetes meeting confirmed that semaglutide users report significantly fewer obsessive thoughts about food. Some users have even reported reduced cravings for alcohol and other compulsive behaviors, pointing to GLP-1's effects on the brain's reward circuitry.

But the picture is not uncomplicated. The side effect profile of GLP-1 drugs extends well beyond the commonly discussed gastrointestinal issues, and the full scope is still emerging.

Gastrointestinal effects remain the most common complaint. Nausea, vomiting, diarrhea, and constipation affect 40-80% of users depending on dose. A 2026 analysis in the Journal of Medical Internet Research found real-world discontinuation rates far exceed clinical trial numbers, with up to 70% of patients stopping treatment within 24 months -- often because of these effects.

Muscle and bone loss is a growing concern. Rapid weight loss on GLP-1 drugs does not discriminate between fat and lean tissue. A secondary analysis of clinical trial data found that up to 40% of weight lost on semaglutide can be lean mass -- muscle and bone -- rather than fat, particularly in women and older adults. Research presented at the 2025 American Academy of Orthopaedic Surgeons meeting found GLP-1 users had approximately 30% higher rates of osteoporosis compared to non-users, and a 2024 phase 2 trial published in eClinicalMedicine showed increased bone resorption markers and lower bone mass at the spine and hip in the semaglutide group versus placebo after 52 weeks. The FDA now notes on semaglutide's label that fracture risk may increase in older adults and women.

Dampened desire and the reward system. Perhaps the most philosophically unsettling side effect is what happens beyond appetite. GLP-1 receptors are densely concentrated in the brain's reward circuitry -- the nucleus accumbens and related structures that govern not just hunger but pleasure, motivation, and desire more broadly. Users widely report the disappearance of "food noise," but some report a broader flattening: reduced interest in alcohol, shopping, socialising, and sex.

Neuroscientists describe this as a dampening of dopamine signalling across reward pathways. Kent Berridge, professor of psychology and neuroscience at the University of Michigan, has noted that GLP-1 drugs may lower the "wanting" component of pleasure -- the motivational drive toward rewarding experiences -- even if the capacity for "liking" remains intact. For some users, this manifests as anhedonia: a clinical term for the inability to experience pleasure that is also a hallmark of depression.

Sexual health effects are increasingly documented. A 2025 database study published in the International Journal of Impotence Research found that non-diabetic obese men prescribed semaglutide for weight loss had a 4.5-fold higher risk of erectile dysfunction and nearly double the risk of testosterone deficiency compared to matched controls not taking the drug. The mechanisms likely involve both the hormonal disruption of rapid fat loss (fat tissue helps regulate oestrogen and testosterone) and the direct effects of GLP-1 receptor activation on dopamine-mediated sexual motivation.

Women report similar variability, with some experiencing improved libido from weight loss and improved body image, while others describe a loss of sexual interest that appears independent of weight changes.

Cost and dependency complete the picture. GLP-1 drugs are expensive, with list prices exceeding $1,000/month in many markets, and studies consistently show that people who stop taking semaglutide regain roughly two-thirds of the weight they lost, raising fundamental questions about whether these drugs represent treatment or lifelong pharmaceutical dependency.

These limitations have driven enormous interest in natural compounds that might work along similar metabolic pathways -- not as drug replacements, but as part of a broader strategy for metabolic health.

How Olive Oil Polyphenols Work in the Body

Polyphenols are a diverse family of plant compounds found in fruits, vegetables, tea, wine, and especially in extra virgin olive oil. If you have ever tasted a high-quality EVOO and felt that characteristic peppery burn at the back of your throat, you have experienced polyphenols at work -- specifically, one called oleocanthal.

But not all polyphenols are the same, and this distinction matters. The polyphenols in blueberries (anthocyanins), green tea (catechins), and red wine (resveratrol) are chemically and functionally different from those found in olive oil. Olive oil contains a unique family of phenolic compounds -- secoiridoids -- that are not found in any other common food source.

The key players are hydroxytyrosol, oleocanthal, oleacein, and oleuropein derivatives. These are produced during the olive fruit's maturation and during the mechanical crushing process that yields virgin olive oil. They are structurally distinct molecules with their own specific biological activities. When research refers to "olive oil polyphenols," it is referring to this unique class of compounds, not to polyphenols in general.

This specificity is important: the metabolic effects described in this article are tied to these olive-derived compounds specifically, not to polyphenols as a broad category.

Their role extends far beyond flavour. Think of these compounds as molecular keys that can turn various biological locks throughout the body. They interact with cellular signalling pathways, modulate inflammation, influence gene expression, and communicate with the gut microbiome. For a deeper introduction to these compounds, the complete scientific guide to polyphenols in olive oil covers the fundamentals.

In the context of metabolic health, three mechanisms stand out.

First, certain polyphenols have potent anti-inflammatory properties. Chronic low-grade inflammation is now understood to be a driver of insulin resistance and leptin resistance -- two processes that fundamentally disrupt the body's ability to regulate weight.

Second, polyphenols can directly interact with metabolic signalling pathways including AMPK (a cellular energy sensor) and NF-kB (a master inflammatory regulator).

Third -- and most relevant to the GLP-1 conversation -- some olive-derived compounds appear to stimulate the very same gut hormone pathways that GLP-1 drugs target pharmacologically.

What the Science Says: Olive Oil, Polyphenols, and Metabolic Health

This is where the research becomes genuinely interesting. Multiple peer-reviewed studies have now demonstrated that extra virgin olive oil influences gut hormone secretion, including GLP-1, in ways that overlap mechanistically with what GLP-1 drugs achieve.

EVOO and gut hormones. 

A 2019 randomized crossover study by Bozzetto et al. published in Clinical Nutrition found that when patients with type 1 diabetes consumed a meal containing EVOO, their postprandial GLP-1 response was significantly higher than when the same meal was consumed with butter or very little fat (Bozzetto et al., 2019). EVOO also slowed early gastric emptying -- the same mechanism that GLP-1 drugs exploit to promote fullness. In a separate study, Garcia-Serrano et al. (2021) demonstrated that a single dose of EVOO produced greater postprandial GLP-1 concentrations than either refined olive oil or sunflower oil, and was associated with decreased ghrelin (the hunger hormone) in subjects including those with morbid obesity.

The elenolic acid discovery. 

Perhaps the most direct link between olive compounds and GLP-1 comes from research led by Dongmin Liu at Virginia Tech, presented at the American Society for Nutrition's 2024 conference. The team identified elenolic acid -- a compound derived from oleuropein, which is abundant in olive fruit and EVOO -- as a direct stimulator of GLP-1 and PYY (peptide YY, another satiety hormone) release from gut L-cells. In obese diabetic mice, oral elenolic acid produced a 10.7% reduction in body weight after four to five weeks, with blood glucose improvements comparable to liraglutide (Liu et al., 2024). The researchers noted, however, that the concentration of elenolic acid in olive oil is low, meaning the benefits seen in this study would likely require concentrated supplementation rather than dietary olive oil alone.

Hydroxytyrosol and metabolic syndrome. 

Hydroxytyrosol, the most studied phenolic compound in olive oil, has shown broad metabolic effects. A comprehensive 2017 review by Peyrol et al. in Nutrients compiled clinical and experimental evidence demonstrating that hydroxytyrosol improves lipid profiles, glycaemia, and insulin sensitivity while counteracting oxidative and inflammatory processes (Peyrol et al., 2017). Cao et al. (2014) showed in a mouse model that hydroxytyrosol prevented diet-induced obesity, hyperglycaemia, and insulin resistance over a 17-week supplementation period, with effects on fasting glucose comparable to metformin. A 2025 randomized, double-blind, placebo-controlled trial published in Clinical Nutrition found that 15 mg/day of hydroxytyrosol improved antioxidant and anti-inflammatory status in overweight individuals with prediabetes over 16 weeks, while preserving insulin sensitivity (Moratilla-Rivera et al., 2025). For a broader look at how these compounds support health, see the health benefits of olive oil polyphenols.

Oleocanthal and inflammation.

 Oleocanthal -- the compound responsible for EVOO's throat-burning peppery sensation -- inhibits COX-1 and COX-2 enzymes in a manner pharmacologically similar to ibuprofen (Lucas et al., 2011). A 2023 randomized crossover trial (the APRIL study) by Santangelo et al. found that EVOO rich in oleocanthal and oleacein significantly improved oxidative and inflammatory markers in people with obesity and prediabetes. Separately, Gualdiero et al. (2020) administered high-oleocanthal EVOO daily for two months to 23 subjects with metabolic syndrome and observed reductions in body weight, waist circumference, BMI, and multiple inflammatory cytokines.

PREDIMED and long-term weight outcomes. 

The landmark PREDIMED trial -- a randomized controlled trial involving 7,447 participants -- demonstrated that a Mediterranean diet supplemented with EVOO (approximately 50 g/day) did not result in weight gain over nearly five years of follow-up, despite being an unrestricted-calorie, high-fat diet (Estruch et al., 2018). In fact, the EVOO group showed a modest reduction in central adiposity. More recently, Guasch-Ferre et al. (2025) analysed 121,119 participants across three US cohorts and found that increased olive oil consumption was inversely associated with long-term body weight changes.

EVOO and gut permeability. 

Bartimoccia et al. (2022) demonstrated in Nutrients that EVOO consumption reduced gut permeability (measured via zonulin) and metabolic endotoxaemia in patients with impaired fasting glucose, while simultaneously increasing postprandial GLP-1 and insulin levels. This finding suggests a dual mechanism: EVOO may support GLP-1 secretion while also reducing the gut-derived inflammation that contributes to metabolic dysfunction.

Does Olive Oil Actually Help You Lose Weight? Can it be a Natural Alternative to Ozempic?

Can olive oil be a natural alternative to Ozempic? Here is where intellectual honesty matters most. The evidence strongly suggests that EVOO, particularly high-polyphenol varieties, supports metabolic health through multiple converging mechanisms: enhanced GLP-1 and PYY secretion, improved insulin sensitivity, reduced inflammation, and modulation of gut permeability. These are real, measurable biochemical effects documented in peer-reviewed research.

But olive oil is not Ozempic. The magnitude of effect is different. GLP-1 drugs produce dramatic, rapid weight loss by maintaining supraphysiological levels of synthetic GLP-1 in the bloodstream around the clock. The GLP-1 response from dietary EVOO, while statistically significant, is part of the normal postprandial hormonal cascade -- a nudge, not a pharmacological override.

What EVOO does appear to do is support the metabolic environment that makes sustainable weight management more achievable. The PREDIMED data is instructive: participants consuming substantial amounts of EVOO in an unrestricted-calorie context did not gain weight -- and showed slight improvements in central adiposity -- over nearly five years. That is a remarkable finding for a high-fat dietary pattern. The Guasch-Ferre cohort analysis suggests that replacing less healthy fats with olive oil is consistently associated with less weight gain over time.

The practical takeaway is that high-polyphenol EVOO is best understood as a metabolic tool within a whole-diet context, not as a standalone weight-loss agent. It works with your biology rather than overriding it. For a broader view of these mechanisms, the health benefits overview provides useful context.

Not All Olive Oils Are Equal: Why Polyphenol Content Matters

This is a critical distinction that often gets lost in general dietary advice. When researchers study EVOO and find metabolic benefits, they are typically using oils with quantified, substantial polyphenol content -- not the refined, months-old bottles that line most supermarket shelves.

A standard commercial EVOO from a supermarket typically contains between 50 and 100 mg/kg of total polyphenols. By the time it has been processed, shipped, and stored under fluorescent lights, much of its phenolic content has degraded through oxidation. This is a fundamentally different product from the fresh, early-harvest, high-polyphenol oils used in clinical research.

The EU recognises this distinction. Commission Regulation (EU) No. 432/2012 permits the health claim that "olive oil polyphenols contribute to the protection of blood lipids from oxidative stress" only for oils containing at least 5 mg of hydroxytyrosol and its derivatives (including the oleuropein complex and tyrosol) per 20 g of oil -- equivalent to roughly 250 mg/kg. This threshold was established based on the EUROLIVE clinical trial data and represents a meaningful minimum for biological activity.

Producers focused on nutraceutical-grade EVOO go significantly beyond this threshold.

Oleaphen, for example, produces an ultra-high polyphenol olive oil with laboratory-verified total polyphenol content exceeding 2,000 mg/kg -- with hydroxytyrosol and oleocanthal as key active compounds.

At these concentrations, a 5 ml daily serving provides polyphenol intake well above the EU-regulated threshold. For a comparison of what to look for when evaluating polyphenol content, the buying guide and 2025 analysis are useful starting points.

How to Use High-Polyphenol Olive Oil for Metabolic Support

Research protocols studying EVOO's metabolic effects typically use daily intakes of 20-50 ml of standard high-quality EVOO -- roughly 1.5 to 3.5 tablespoons. The PREDIMED trial provided participants with approximately 50 ml per day (about one litre per week for household use). The EU health claim references 20 g per day (approximately 1.5 tablespoons) as the minimum for health benefits from oils meeting the 250 mg/kg polyphenol threshold.

With ultra-high polyphenol oils like Oleaphen, where concentrations exceed 2,000 mg/kg, a much smaller serving -- as little as 5 ml per day -- delivers comparable or greater polyphenol intake. This makes it practical to take as a daily supplement rather than needing to incorporate large volumes into cooking.

Timing can also play a role. Taking EVOO with or just before a meal aligns with how GLP-1 is naturally produced -- in response to food entering the gut. Some evidence suggests that taking it before the largest meal of the day may optimise the postprandial hormone response. The timing guide explores this topic in more detail.

Consistency matters more than any single dose. The metabolic benefits documented in the research emerge over weeks and months of regular consumption, not from occasional use. Pairing high-polyphenol EVOO with a Mediterranean-pattern diet -- rich in vegetables, legumes, fish, and whole grains -- provides the broader nutritional context in which these compounds work best.

The Bigger Picture: Food as Metabolic Medicine

The conversation around GLP-1 drugs has done something genuinely valuable: it has reframed weight management as a metabolic and hormonal challenge rather than a failure of willpower. That shift in understanding is important regardless of how any individual chooses to address it.

What the olive oil polyphenol research adds to this picture is the recognition that food itself can participate in metabolic signalling in meaningful ways. Compounds like hydroxytyrosol, oleocanthal, oleuropein, and elenolic acid are not passive nutrients -- they are bioactive molecules that interact with the same cellular and hormonal systems that pharmaceutical agents target. The difference is one of scale and specificity, not of kind.

This is not about choosing between medicine and food. It is about recognising that a diet rich in bioactive compounds -- particularly high-polyphenol extra virgin olive oil -- can support the metabolic infrastructure that keeps hunger, inflammation, insulin sensitivity, and body composition in a healthier range. The evidence is not hypothetical. It is published, peer-reviewed, and growing.

The ancient Mediterranean instinct to build meals around olive oil turns out to have a remarkably sophisticated biochemical rationale. We are only beginning to understand how deep it goes.

FAQ

Q: Is olive oil a GLP-1 agonist?

No, olive oil is not a GLP-1 receptor agonist in the pharmacological sense. GLP-1 drugs like semaglutide are synthetic molecules designed to bind to and activate GLP-1 receptors directly, maintaining elevated GLP-1 activity for extended periods. What clinical studies have shown is that consuming extra virgin olive oil stimulates your body's own natural GLP-1 secretion from gut L-cells as part of the normal postprandial hormonal response. This is a meaningful biological effect, but it operates at a different scale and duration than pharmaceutical GLP-1 agonists.

Q: How much olive oil per day for metabolic benefits?

Research protocols typically use 20-50 ml per day of standard high-quality EVOO. The EU health claim under Regulation 432/2012 references a minimum of 20 g (approximately 1.5 tablespoons) per day for oils containing at least 250 mg/kg of hydroxytyrosol and its derivatives. With ultra-high polyphenol oils exceeding 2,000 mg/kg, a daily serving of 5 ml can provide equivalent or greater polyphenol intake. Consistency of daily intake appears to be parramount.

Q: What polyphenol level should I look for in olive oil?

For meaningful biological activity, look for oils with verified polyphenol content of at least 500 mg/kg. Many standard EVOOs fall below this level, particularly after extended shelf time. Nutraceutical-grade oils typically contain 1000 mg/kg or higher, with some ultra-high polyphenol varieties exceeding 2,000 mg/kg. Always look for IOC accredited, laboratory-verified polyphenol content rather than general marketing claims.(HPLC, LC-Ms/Ms

Q: Can I take olive oil instead of Ozempic?

No. Olive oil and GLP-1 receptor agonist medications serve fundamentally different purposes and operate at different scales of effect. GLP-1 drugs are FDA-approved pharmaceuticals for treating type 2 diabetes and obesity, prescribed under medical supervision. High-polyphenol EVOO is a nutritional tool that may support metabolic health through multiple mechanisms, including modest support of natural GLP-1 secretion. It should not be considered a substitute for any prescribed medication. Anyone considering changes to their medication should consult their healthcare provider.

Q: Does olive oil reduce appetite?

Clinical evidence suggests that EVOO can influence appetite-related hormones. Studies have shown that EVOO consumption increases postprandial GLP-1 and PYY (both satiety hormones) while decreasing ghrelin (the hunger hormone) compared to other dietary fats. The monounsaturated fatty acid oleic acid in olive oil also stimulates production of oleoylethanolamide (OEA), a gut-derived lipid messenger that enhances satiety. These effects contribute to the finding that EVOO-rich diets do not promote weight gain despite being calorie-dense.

Q: What is hydroxytyrosol?

Hydroxytyrosol is the most abundant and most studied phenolic compound in extra virgin olive oil. It is classified as a potent antioxidant with demonstrated effects on lipid metabolism, insulin sensitivity, and inflammation in both animal and human studies. The European Food Safety Authority recognises hydroxytyrosol (along with its derivatives including the oleuropein complex and tyrosol) as the specific polyphenol group responsible for olive oil's ability to protect blood lipids from oxidative stress. It has high bioavailability compared to many other dietary polyphenols.

Q: How long before I see metabolic effects from high-polyphenol olive oil?

The timeline depends on what you are measuring. Acute effects on postprandial GLP-1 secretion and blood glucose response occur within hours of a single dose. Changes in inflammatory markers and oxidative stress biomarkers have been observed in clinical trials over periods of 4-16 weeks. Longer-term metabolic benefits, including effects on body composition and insulin sensitivity, typically emerge over months of consistent daily consumption, consistent with the timeframes seen in trials like PREDIMED (median follow-up of 4.8 years).

Q: Is high-polyphenol olive oil safe?

Extra virgin olive oil has been consumed as a dietary staple for thousands of years across Mediterranean populations with well-documented health outcomes. The European Food Safety Authority has reviewed the evidence for olive oil polyphenols and authorised a specific health claim based on that review. Clinical trials using high-polyphenol EVOO at doses consistent with the research discussed in this article have not reported significant adverse effects. As with any dietary change, individuals with specific medical conditions or those on medication should discuss with their healthcare provider.

References

1. Bozzetto, L., Alderisio, A., Giorgini, M., et al. (2019). Gastrointestinal effects of extra-virgin olive oil associated with lower postprandial glycemia in type 1 diabetes. Clinical Nutrition, 38(6), 2645-2651. DOI: 10.1016/j.clnu.2018.11.015

2. Garcia-Serrano, S., Ho-Plagaro, A., Santiago-Fernandez, C., et al. (2021). An isolated dose of extra-virgin olive oil produces a better postprandial gut hormone response, lipidic, and anti-inflammatory profile than sunflower oil: Effect of morbid obesity. Molecular Nutrition & Food Research, 65(22), e2100071. DOI: 10.1002/mnfr.202100071

3. Liu, D., Alkhalidy, H., et al. (2024). An olive-derived elenolic acid stimulates hormone release from L-cells and exerts potent beneficial metabolic effects in obese diabetic mice. Presented at NUTRITION 2024, American Society for Nutrition Annual Meeting, Chicago. Published in Frontiers in Nutrition.

4. Peyrol, J., Riva, C., & Amiot, M.J. (2017). Hydroxytyrosol in the prevention of the metabolic syndrome and related disorders. Nutrients, 9(3), 306. DOI: 10.3390/nu9030306

5. Cao, K., Xu, J., Zou, X., et al. (2014). Hydroxytyrosol prevents diet-induced metabolic syndrome and attenuates mitochondrial abnormalities in obese mice. Free Radical Biology and Medicine, 67, 396-407. DOI: 10.1016/j.freeradbiomed.2013.11.029

6. Moratilla-Rivera, I., Perez-Jimenez, J., Ramos, S., et al. (2025). Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial. Clinical Nutrition, 44, 365-376.

7. Lucas, L., Russell, A., & Keast, R. (2011). Molecular mechanisms of inflammation. Anti-inflammatory benefits of virgin olive oil and the phenolic compound oleocanthal. Current Pharmaceutical Design, 17(8), 754-768. DOI: 10.2174/138161211795428911

8. Santangelo, C., Vari, R., Scazzocchio, B., et al. (2023). Rich oleocanthal and oleacein extra virgin olive oil and inflammatory and antioxidant status in people with obesity and prediabetes. The APRIL study: A randomised, controlled crossover study. Clinical Nutrition, 42(8), 1389-1398. DOI: 10.1016/j.clnu.2023.06.027

9. Gualdiero, P., Ferrara, L., Ferrara, E., et al. (2020). Daily use of extra virgin olive oil with high oleocanthal concentration reduced body weight, waist circumference, alanine transaminase, inflammatory cytokines and hepatic steatosis in subjects with the metabolic syndrome: A 2-month intervention study. Antioxidants, 9(10), 941. DOI: 10.3390/antiox9100941

10. Estruch, R., Ros, E., Salas-Salvado, J., et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine, 378(25), e34. DOI: 10.1056/NEJMoa1800389

11. Guasch-Ferre, M., Pacheco, L.S., Tessier, A.J., et al. (2025). Changes in olive oil consumption and long-term body weight changes in 3 United States prospective cohort studies. American Journal of Clinical Nutrition, 121(5), 1149-1156. DOI: 10.1016/j.ajcnut.2025.02.012

12. Bartimoccia, S., Cammisotto, V., Nocella, C., et al. (2022). Extra virgin olive oil reduces gut permeability and metabolic endotoxemia in diabetic patients. Nutrients, 14(10), 2153. DOI: 10.3390/nu14102153

13. Khanal, P., Oh, W.K., Yun, H.J., et al. (2011). p-HPEA-EDA, a phenolic compound of virgin olive oil, activates AMP-activated protein kinase to inhibit carcinogenesis. Carcinogenesis, 32(4), 545-553. DOI: 10.1093/carcin/bgr001

14. Guasch-Ferre, M., Li, Y., Willett, W.C., et al. (2022). Consumption of olive oil and risk of total and cause-specific mortality among U.S. adults. Journal of the American College of Cardiology, 79(2), 101-112. DOI: 10.1016/j.jacc.2021.10.041